Figure 6.
Prognostic impact of dual-modality MRD negativity. PFS in patients who achieved negativity in both the peripheral blood and bone marrow compared with those negative in only 1 of the analyzed modalities (A-C). PFS based on the combination of LC-MS and 10−6 NGS MRD results (D).
